Ontology highlight
ABSTRACT:
SUBMITTER: Reuter SE
PROVIDER: S-EPMC6363066 | biostudies-other | 2019 Jan
REPOSITORIES: biostudies-other
Reuter Stephanie E SE Evans Allan M AM Ward Michael B MB
CPT: pharmacometrics & systems pharmacology 20181205 1
Palivizumab for respiratory syncytial virus (RSV) immunoprophylaxis in premature infants poses a significant economic challenge. Although standard dosing of palivizumab results in unnecessary drug accumulation without additional clinical benefit, some clinicians have moved outside of evidence-based practice by implementing untested dose modifications, potentially jeopardizing efficacy. Using an industry-developed population pharmacokinetic model, this study evaluated the previously published alt ...[more]